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Where Are Your Drugs Really Made and Who is 
Regulating it? 
November 23, 2012 
By: Floyd Trillis III, Associate, The Global Business Law Review 
Over the last decade, the pharmaceutical supply chain has become increasingly 
globalized. Up to 40% of all drugs Americans take are imported, and about 80% of the 
active ingredients in those drugs come from foreign sources.[1] The U.S. FDA has 
struggled to conduct inspections of these foreign facilities, especially in emerging 
markets, due to a lack of appropriate resources and funding.[2] 
To address the growing number of regulatory challenges the FDA and representatives of 
the generic drug industry negotiated an agreement that ultimately passed into law on July 
9, 2012 as the Generic Drug User Fee Amendment (GDUFA).[3] The agreement marked 
the first time ever in which the FDA would receive funding from the generic drug 
industry.[4] A portion of the money would be used to underwrite inspections of 
manufacturing facilities in foreign countries, which would be held every two years – the 
same frequency required for manufacturing facilities in the U.S.[5] 
Beginning on October 1, 2012, the annual funding from GDUFA user fees is set at $229 
million and will come from application fees (ANDAs and DMFs) as well as annual 
facility fees.[6] The GDUFA fees will be imposed on both API and finished dose 
manufacturers which will ensure that all participants appropriately share the financial 
expense and benefits of the program. While the FDA has publicized information about 
the proposed user fee structure, the actual fee amounts will not be determined until 
months after GDUFA launches.[7] Non-payment of annual facility fees from API and/or 
finished dose manufacturers will result in all products from those facilities being 
classified as misbranded and banned from sale in the U.S. market.[8] 
In a Commitment Letter that accompanied the legislation, the FDA vowed to review and 
act on 90% of original ANDAs within 10 months following the date of submission by 
year five of the program.[9] This will reduce the overall expense of bringing a generic 
product to market, and deliver safe, effective, and affordable generic drugs to the public 
sooner.[10] Most notably, the implementation of GDUFA will force generic drug 
manufacturers to accept responsibility for the relationships that they have with their 
foreign suppliers and for the products they put out to the market.[11] 
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